Neoadjuvant chemotherapy with epirubicin, cisplatin, and capecitabine (ECX) does not improve survival compared with cisplatin and fluorouracil (CF) among patients with esophageal cancer, according to a study published in The Lancet Oncology.1
http://www.cancertherapyadvisor.com/gastrointestinal-cancers/esophageal-cancer-neoadjuvant-cisplatin-epirubicin-capecitabine-vs-cisplatin-fluorouracil/article/680267/
Neoadjuvant Cisplatin, Epirubicin, and Capecitabine vs Cisplatin and Fluorouracil for Esophageal Cancer